STRS Ohio’s Aktis Oncology AKTS Stock Holding History

STRS Ohio’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.4K	Buy	+3,600	New	+$69.9K	﹤0.01%	1886

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

STRS Ohio's AKTS Position: Q1 2026 in Review

STRS Ohio opened a new position in Aktis Oncology (AKTS) in Q1 2026: 3,600 shares worth $64.4K. The stake represents ﹤0.01% of the portfolio and ranks #1886 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

STRS Ohio held 3,600 shares of Aktis Oncology worth $64.4K as of Q1 2026.
Aktis Oncology was a new STRS Ohio position in Q1 2026.
Aktis Oncology made up ﹤0.01% of STRS Ohio's portfolio in Q1 2026, its #1886 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.